Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells

Leukemia

Volumn 22, Issue 4, 2008, Pages 819-825

  Inoue, S ^a   Walewska, R ^a   Dyer, M J S ^a   Cohen, G M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; CYCLIN DEPENDENT KINASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PANOBINOSTAT; PROTEIN MCL 1; ROSCOVITINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL STRAIN K 562; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; UPREGULATION;

EID: 42349095198     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.1     Document Type: Article

References (44)

1. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-219.
2. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
3. Huang DC, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-842.
4. Labi V, Erlacher M, Kiessling S, Villunger A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 2006; 13: 1325-1338.
5. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.
6. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002; 100: 1795-1801.
7. Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005; 105: 4820-4827.
8. Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002; 16: 444-454.
9. Michels J, Johnson PW, Packham G. Mcl-1. Int J Biochem Cell Biol 2005; 37: 267-271.
10. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307: 1101-1104.
11. Fritsch RM, Schneider G, Saur D, Scheibel M, Schmid RM. Translational repression of MCL-1 couples stress-induced elF2 alpha phosphorylation to mitochondrial apoptosis initiation. J Biol Chem 2007; 282: 22551-22562.
12. Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Gimenez MS et al Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther 2007; 6: 692-702.
13. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidyl-inositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 1999; 19: 6195-6206.
14. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J et al. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 2002; 277: 43730-43734.
15. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006; 21: 749-760.
16. Mandelin II AM, Pope RM. Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 2007; 11: 363-373.
17. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003; 17: 1475-1486.
18. Snowden RT, Sun XM, Dyer MJ, Cohen GM. Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1. Leukemia 2003; 17: 1981-1989.
19. Adams KW, Cooper GM. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem 2007; 282: 6192-6200.
20. Cuconati A, Mukherjee C, Perez D, White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev 2003; 17: 2922-2932.
21. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
22. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-168.
23. Rosato RR, Grant S. Histone deacelylase inhibitors: Insights into mechanisms of lethality. Expert Opin Ther Targets 2005; 9: 809-824.
24. Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ 2006; 13: 129-140.
25. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005; 102: 16090-16095.
26. Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by, Bim and Noxa. Leukemia 2007; 21: 1773-1782.
27. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004; 11: S193-S206.
28. Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006; 66: 6785-6792.
29. Brown GR, Bamford AM, Bowyer J, James DS, Rankine N, Tang E et al. Naphthyl ketones: A new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett 2000; 10: 575-579.
30. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006, 107: 4109-4114.
31. Michels J, O'Neill JW, Dallman CL, Mouzakiti A, Habens F, Brimmell M et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage, Oncogene 2004; 23: 4818-4827.
32. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B et al Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006; 12 634-642.
33. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-738.
34. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: Mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106: 2513-2519.
35. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphlocytic leukemia. Blood 2000; 96: 393-397.
36. Strasser A, Puthalakath H. Fold up or perish: Unfolded protein response and chemotherapy. Cell Death Differ 2008; 15: 223-225.
37. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC et al Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007; 104: 6217-6222.
38. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121: 1085-1095.
39. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007; 67: 2908-2911.
40. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
41. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783.
42. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 2006; 281: 10153-10163.
43. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12: 66-80.
44. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64: 3517-3524.